Mesa Laboratories Dirección

Dirección controles de criterios 3/4

El CEO de Mesa Laboratories' es Gary Owens , nombrado en Sep 2017, tiene una permanencia de 6.58 años. compensación anual total es $5.19M, compuesta por 14.1% salario y 85.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.56% de las acciones de la empresa, por valor de $3.06M. La antigüedad media del equipo directivo y de la junta directiva es de 6.6 años y 3.9 años, respectivamente.

Información clave

Gary Owens

Chief Executive Officer (CEO)

US$5.2m

Compensación total

Porcentaje del salario del CEO	14.1%
Permanencia del CEO	6.7yrs
Participación del CEO	0.6%
Permanencia media de la dirección	6.7yrs
Promedio de permanencia en la Junta Directiva	4yrs

Actualizaciones recientes de la dirección

Recent updates

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

May 03

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Mar 15

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

May 31

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Apr 12

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Mar 13

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Dec 20

Mesa Laboratories declares $0.16 dividend

Oct 03

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Sep 09

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

Sep 06

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Aug 08

Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M

Aug 04

Mesa Laboratories declares $0.16 dividend

Jul 07

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

May 06

Growth Investors: Industry Analysts Just Upgraded Their Mesa Laboratories, Inc. (NASDAQ:MLAB) Revenue Forecasts By 14%

Apr 09

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

Dec 08

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gary Owens en comparación con los beneficios de Mesa Laboratories?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	US$948k
Sep 30 2023	n/a	n/a	-US$717k
Jun 30 2023	n/a	n/a	US$2m
Mar 31 2023	US$5m	US$733k	US$930k
Dec 31 2022	n/a	n/a	-US$1m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$2m
Mar 31 2022	US$18m	US$579k	US$2m
Dec 31 2021	n/a	n/a	US$8m
Sep 30 2021	n/a	n/a	US$5m
Jun 30 2021	n/a	n/a	US$4m
Mar 31 2021	US$3m	US$524k	US$3m
Dec 31 2020	n/a	n/a	-US$2m
Sep 30 2020	n/a	n/a	-US$2m
Jun 30 2020	n/a	n/a	-US$2m
Mar 31 2020	US$3m	US$600k	US$2m
Dec 31 2019	n/a	n/a	US$5m
Sep 30 2019	n/a	n/a	US$10m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	US$3m	US$520k	US$7m
Dec 31 2018	n/a	n/a	US$10m
Sep 30 2018	n/a	n/a	-US$2m
Jun 30 2018	n/a	n/a	-US$249k
Mar 31 2018	US$1m	US$417k	-US$3m

Compensación vs. Mercado: La compensación total de Gary($USD5.19M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.37M).

Compensación vs. Ingresos: La compensación de Gary ha sido consistente con los resultados de la empresa en el último año.

CEO

Gary Owens (55 yo)

6.7yrs

Permanencia

US$5,190,371

Compensación

Mr. Gary M. Owens has been Chief Executive Officer, President and Director of Mesa Laboratories, Inc. since September 1, 2017. Mr. Owens joined as Chief Operating Officer in March 2017. Mr. Owens served as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gary Owens	CEO, President & Director	6.7yrs	US$5.19m	0.56% $ 3.5m
John Sakys	VP, CFO & Chief Accounting Officer	11.6yrs	US$1.91m	0.52% $ 3.2m
Brian Archbold	Senior Vice President of Continuous Improvement	6.3yrs	US$1.46m	0.010% $ 64.5k

6.7yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MLAB es experimentado (6.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gary Owens	CEO, President & Director	6.7yrs	US$5.19m	0.56% $ 3.5m
Shiraz Ladiwala	Lead Independent Director	2.6yrs	US$217.55k	0.028% $ 173.6k
John Sullivan	Chairman of the Board	15.2yrs	US$255.10k	1.33% $ 8.3m
R. Tripeny	Independent Director	1.9yrs	US$219.97k	0.030% $ 185.8k
Mark Capone	Director	less than a year	sin datos	sin datos
Shannon Hall	Independent Director	4yrs	US$220.10k	0.032% $ 198.0k
Jennifer Alltoft	Independent Director	5.2yrs	US$210.10k	0.044% $ 277.7k

4.0yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de MLAB se considera experimentada (3.9 años de antigüedad promedio).

Mesa Laboratories Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

CEO, President & Director exercised options and sold US$166k worth of stock

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

Recent updates

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

Third quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024

Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Consensus EPS estimates upgraded to US$0.055 loss

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024

Insider notifies of intention to sell stock

Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024

Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?

Upcoming dividend of US$0.16 per share at 0.7% yield

Price target decreased by 17% to US$115

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.

Price target decreased by 8.9% to US$139

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?

Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023

CEO, President & Director notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.5% yield

Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt

Now 20% undervalued after recent price drop

Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023

CEO, President & Director exercised options and sold US$166k worth of stock

Consensus EPS estimates increase by 14%

Now 21% undervalued after recent price drop

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

Price target decreased by 11% to US$178

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of US$0.16 per share at 0.4% yield

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.4% yield

VP, CFO & Chief Accounting Officer exercised options and sold US$132k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VP, CFO & Chief Accounting Officer exercised options and sold US$293k worth of stock

Independent Director exercised options and sold US$137k worth of stock

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Mesa Laboratories, Inc. to Report Q3, 2023 Results on Feb 06, 2023

Upcoming dividend of US$0.16 per share

Now 21% undervalued after recent price drop

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH.

Mesa Laboratories, Inc. Appoints Tony Tripeny as Member of Audit Committee

Second quarter 2023 earnings released: EPS: US$0.24 (vs US$0.71 in 2Q 2022)

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2022

Mesa Laboratories declares $0.16 dividend

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

VP, CFO & Chief Accounting Officer exercised options and sold US$143k worth of stock

Upcoming dividend of US$0.16 per share

Independent Director recently sold US$198k worth of stock

VP, CFO & Chief Accounting Officer exercised options and sold US$260k worth of stock

Independent Director recently bought US$100k worth of stock

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Now 21% undervalued after recent price drop